We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+12.82%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$13.3B
AUM Growth
+$1.51B
Cap. Flow
+$1.01B
Cap. Flow %
7.58%
Top 10 Hldgs %
83.56%
Holding
124
New
10
Increased
16
Reduced
22
Closed
5

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$1.09B
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$97.2M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$84.2M
4
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$54.3M
5
TCDA
Tricida, Inc. Common Stock
TCDA
+$44.7M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$144M
2
ABLX
Ablynx NV
ABLX
+$119M
3
NKTR icon
Nektar Therapeutics
NKTR
+$29.3M
4
EXEL icon
Exelixis
EXEL
+$13.4M
5
PGNX
Progenics Pharmaceuticals Inc
PGNX
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 92.38%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INFI
101
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.11M 0.01%
580,400
– –
TTOO
102
DELISTED
T2 Biosystems, Inc
TTOO
$774K 0.01%
20
– –
JNCE
103
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$766K 0.01%
100,000
– –
TARA icon
104
Protara Therapeutics
TARA
$216M
$732K 0.01%
7,465
– –
AIXC
105
AIxCrypto Holdings Inc
AIXC
$13.4M
$720K 0.01%
22
– –
STML
106
DELISTED
Stemline Therapeutics, Inc.
STML
$715K 0.01%
44,524
-243,303
-85% -$4.34M
AFMD
107
DELISTED
Affimed
AFMD
$660K 0.01%
40,000
– –
BDSI
108
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$620K ﹤0.01%
210,021
– –
FLGT icon
109
Fulgent Genetics
FLGT
$564M
$518K ﹤0.01%
125,000
– –
MTEM
110
DELISTED
Molecular Templates, Inc.
MTEM
$379K ﹤0.01%
4,827
– –
AKTX
111
Akari Therapeutics
AKTX
$14.7M
$115K ﹤0.01%
73
-352
-83% -$553K
BGMSP
112
DELISTED
Bio Green Med Solution Inc Preferred Stock
BGMSP
$89K ﹤0.01%
13,253
– –
BTX.WS
113
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
$1K ﹤0.01%
20,084
– –
NKTR icon
114
Nektar Therapeutics
NKTR
$2.35B
– –
-18,360
Closed -$29.3M
NVAX icon
115
Novavax
NVAX
$1.22B
– –
-100,000
Closed -$4.2M
ABLX
116
DELISTED
Ablynx NV
ABLX
– –
-2,176,802
Closed -$119M
AVXS
117
DELISTED
AveXis, Inc. Common Stock
AVXS
– –
-1,167,157
Closed -$144M
IMDZ
118
DELISTED
Immune Design Corp.
IMDZ
– –
-148,937
Closed -$491K
1 2 3 4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2018 Portfolio in Review

As of Q2 2018, Baker Bros. Advisors held 124 positions worth $13.3B, up 13% from $11.8B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Baker Bros. Advisors deployed $1.01B of net new capital in Q2 2018, opening 10 new positions and adding to 16 existing holdings. Its largest new stake was Kiniksa Pharmaceuticals: 3,000,000 shares worth $52M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 94% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Exelixis, an estimated $13.4M trimmed.

  • Baker Bros. Advisors's largest Q2 2018 buy was Kiniksa Pharmaceuticals: 3,000,000 shares worth $52M.
  • Baker Bros. Advisors added most to BeOne Medicines Ltd in Q2 2018, an estimated $1.09B increase.
  • Baker Bros. Advisors's biggest Q2 2018 reduction was Exelixis, cutting an estimated $13.4M.
  • Baker Bros. Advisors fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $144M.
  • Baker Bros. Advisors's ten largest holdings make up 84% of its $13.3B portfolio in Q2 2018.
  • Baker Bros. Advisors opened 10 new positions and closed 5 in Q2 2018.
  • Baker Bros. Advisors's portfolio value rose 13% quarter-over-quarter to $13.3B.

Based on Baker Bros. Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.